MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
GenKyoTex Starts Phase 1 Trial with First in Class NOX inhibitor GKT137831. Dual NOX1/4 Inhibitor Targets Treatment of Diabetic Nephropathy.
Brennan CaruthersOctober 31, 2011
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

Syndexa Pharmaceuticals Expands Series B1 Financing Round with Investment by MP Healthcare Venture Management, Inc.

Brennan CaruthersDecember 30, 2011
Next

F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted Biologics.

Brennan CaruthersSeptember 7, 2011

© 2010-2019 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact